FDA approves Scopus BioPharma's IND application for CpG-STAT3siRNA.

The distinctive immuno-oncology RNA therapy targets multiple types of cancers.
Scopus BioPharma shares jumped 200% in the stock market on Monday morning.
Scopus BioPharma Inc. (NASDAQ: SCPS) said the U.S. Food and Drug Administration FDA approved its IND (investigational new drug) application on Monday for CpG-STAT3siRNA – its distinctive immuno-oncology RNA therapy that targets multiple types of cancers.
Impact on the share price
Following the announcement, Scopus BioPharma jumped roughly 200% in the stock market on Monday morning. The company touched a high of $15.42 per share (£10.90 per share) and is currently exchanging hands at $12.54 per share. In comparison, Scopus had started the year 2021 at a per-share price of $13.41.

Related Keywords

California ,United States ,Marcin Kortylewski ,Zhua Yu ,Scopus Biopharma ,Scopus Biopharma Inc ,Drug Administration ,Department Of Immuno ,Nasdaq ,Nasdaq Stock Exchange ,Hodgkin Lymphoma ,Beckman Research Institute ,கலிஃபோர்னியா ,ஒன்றுபட்டது மாநிலங்களில் ,ஹுவா யூ ,துறை ஆஃப் இம்யூனோ ,நாஸ்டாக் ,நாஸ்டாக் ஸ்டாக் பரிமாற்றம் ,ஹாட்ஜ்கின் லிம்போமா ,பெக்மேன் ஆராய்ச்சி நிறுவனம் ,